SCHEMBL27166157

SCHEMBL27166157

N#CC(=C1CCN(C(=O)N2CCc3[nH]ncc3C2)CC1)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PROKR1 Q8TCW9 1/20 0.49
NAMPT P43490 3/20 0.40
ABL1 P00519 3/20 0.38
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CCNA1 P78396 1/20 0.36
PDE4B Q07343 1/20 0.35
PDE4D Q08499 1/20 0.35
ENPP2 Q13822 1/20 0.34
ATXN2 Q99700 1/20 0.34
CFTR P13569 1/20 0.34
HSD11B1 P28845 1/20 0.34
MGLL Q99685 1/20 0.33
EPHX2 P34913 1/20 0.33
F2R P25116 1/20 0.33
SPR P35270 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
ABCB1 P08183 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27166038 0.87 NAMPT (0.52) PROKR1NAMPTENPP2SPRHTR2A
SCHEMBL27166043 0.85 PROKR1 (0.45) PROKR1NAMPTENPP2SPR
SCHEMBL30055886 0.82 NAMPT (0.45) PROKR1NAMPTCCNA2CDK2CCNA1
SCHEMBL29205147 0.82 NAMPT (0.39) PROKR1NAMPTENPP2SPR
SCHEMBL27166042 0.82 NAMPT (0.45) PROKR1NAMPTCCNA2CDK2CCNA1
SCHEMBL27166147 0.81 NAMPT (0.45) PROKR1NAMPTENPP2SPR
SCHEMBL27166178 0.81 PROKR1 (0.46) PROKR1NAMPTPDE4BPDE4DENPP2
SCHEMBL27166096 0.80 PROKR1 (0.47) PROKR1NAMPTPDE4BPDE4DHSD11B1
SCHEMBL29205134 0.78 PROKR1 (0.45) PROKR1NAMPTABL1ENPP2ATXN2
SCHEMBL27166199 0.78 PROKR1 (0.45) PROKR1NAMPTPDE4BPDE4DENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637471-B2 Heterocyclic compounds, compositions, methods of preparation and uses thereof ORGANON R&D FINLAND LTD. (FI) 2026-05-26 US disclosed
EP-4334289-B1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF Organon R&D Finland Oy (FI) 2025-06-25 EP disclosed
US-20240254131-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF ORGANON R&D FINLAND LTD. (FI) 2024-08-01 US disclosed
CN-117794899-A Novel heterocyclic compounds, compositions, methods of preparation and uses thereof 欧加农研发芬兰有限公司 2024-03-29 CN disclosed
EP-4334289-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF Organon R&D Finland Ltd (FI) 2024-03-13 EP disclosed
WO-2022234193-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF FORENDO PHARMA LTD (FI) 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254131-A1 NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF AKR1C3, AKR1C4, AKR1C1 PROKR1 1639/4885NAMPT 602/4885ABL1 4537/4885
US-12637471-B2 Heterocyclic compounds, compositions, methods of preparation and uses thereof AKR1C3, AKR1C4, AKR1C2 PROKR1 1682/4885NAMPT 2385/4885ABL1 4590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.